Skip to content
10-Q

Quarterly Report

Crinetics Pharmaceuticals, Inc. CRNX

0001658247-26-000040

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 23, 2026 105.44M sh
Shares Diluted Q1 2026 · Mar 31, 2026 104.1M sh
Shares Diluted Q1 2026 · Mar 31, 2025 93.1M sh
Capex Q1 2026 · Mar 31, 2026 $820K
Capex Q1 2026 · Mar 31, 2025 $1.24M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$124.7M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$88.45M
Short Term Investments Q1 2026 · Mar 31, 2026 $1.18B
Short Term Investments Q1 2026 · Dec 31, 2025 $926.35M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $114.34M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $101.54M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $94.57M
Stockholders Equity Q1 2026 · Mar 31, 2026 $1.28B
Stockholders Equity Q1 2026 · Dec 31, 2025 $992.08M
Stockholders Equity Q1 2026 · Mar 31, 2025 $1.25B
Stockholders Equity Q1 2026 · Dec 31, 2024 $1.32B
Current Liabilities Q1 2026 · Mar 31, 2026 $71.09M
Current Liabilities Q1 2026 · Dec 31, 2025 $85.07M
Total Liabilities Q1 2026 · Mar 31, 2026 $120.68M
Total Liabilities Q1 2026 · Dec 31, 2025 $134.17M
Current Assets Q1 2026 · Mar 31, 2026 $1.32B
Current Assets Q1 2026 · Dec 31, 2025 $1.05B
Total Assets Q1 2026 · Mar 31, 2026 $1.4B
Total Assets Q1 2026 · Dec 31, 2025 $1.13B
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.23
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.04
Eps Basic Q1 2026 · Mar 31, 2026 −$1.23
Eps Basic Q1 2026 · Mar 31, 2025 −$1.04
Rd Expense Q1 2026 · Mar 31, 2026 $100.08M
Rd Expense Q1 2026 · Mar 31, 2025 $76.24M
Net Income Q1 2026 · Mar 31, 2026 −$127.85M
Net Income Q1 2026 · Mar 31, 2025 −$96.77M
Operating Income Q1 2026 · Mar 31, 2026 −$140.38M
Operating Income Q1 2026 · Mar 31, 2025 −$111.41M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $200K
Cost Of Revenue Q1 2026 · Mar 31, 2025 $0
Revenue Q1 2026 · Mar 31, 2026 $10.73M
Revenue Q1 2026 · Mar 31, 2025 $361K